An Open-Label, Dose Escalation, Phase 1 Study of Tranylcypromine (TCP) in Combination With ATRA (Tretinoin) for Adult Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Trial Profile

An Open-Label, Dose Escalation, Phase 1 Study of Tranylcypromine (TCP) in Combination With ATRA (Tretinoin) for Adult Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Tranylcypromine (Primary) ; Tretinoin (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Feb 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
    • 22 Sep 2015 10 mg study drug dose was removed from the study, as reported by ClinicalTrials.gov record.
    • 22 Sep 2015 Planned number of patients changed from 24 to 25, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top